Safety evaluation of selective estrogen receptor degraders (SERDs) using real-world evidence from the FDA Adverse Event Reporting System (FAERS) Authors: Ye Kang, Xue Sun, Da-sheng Dang, Yuan Yuan Published: 2025 ABSTRACT This study aims to evaluate post-marketing adverse event data for two selective estrogen receptor degraders (SERDs) in a real-world context, identify potential risk signals, and offer insights for clinical pharmacovigilance. Data were extracted from the U.S. FDA Adverse Event Reporting System (FAERS) database, covering the period from Q1 2004 to Q4 2024. The analysis commenced with elacestrant (2022) and fulvestrant (2004), concluding in the fourth quarter of 2024. Data standardization was achieved using MedDRA version 27.0. Signal detection employed four methodologies: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS). A total of 6,636 adverse event (AE) reports identified elacestrant as the primary suspected drug, while 9,120 reports identified fulvestrant as the primary suspected drug. Both drugs commonly induced adverse reactions such as nausea, vomiting, disease progression, elevated liver enzymes, and hot flashes. Elacestrant was frequently associated with abnormal tumor markers and esophageal-related reactions. In contrast, fulvestrant was linked to a higher incidence of tumor metastasis and may also affect the hematological and lymphatic systems, as well as the cardiovascular and respiratory systems. Both classes of SERDs demonstrated a generally favorable overall safety profile, although differences were noted in their specific adverse reaction profiles. For elacestrant, particular attention should be given to dehydration, abnormal tumor markers, and esophageal-related reactions. For fulvestrant, increased vigilance is necessary regarding cancer metastasis and adverse events impacting the hematological and lymphatic systems. It is recommended that targeted monitoring be enhanced in clinical practice in accordance with the distinct characteristics of each drug.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-26351-z. Introduction Breast cancer, recognized as one of the most prevalent malignant tumors among women worldwide, has witnessed a paradigm shift in treatment strategies from traditional chemotherapy to precision-targeted therapies. The estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) subtype constitutes the most common form of breast cancer, representing approximately 65%-70% of adverse event reports1. Despite the widespread use of aromatase inhibitors (such as letrozole, anastrozole, and exemestane) and selective estrogen receptor modulators (such as tamoxifen and toremifene) in the management of early-stage and advanced breast cancer, treatment failure occurs in approximately 30–50% of patients due to ESR1 mutations or acquired resistance2. Selective estrogen receptor degraders (SERDs), including fulvestrant and elacestrant, offer a novel therapeutic approach by directly binding to and promoting the degradation of estrogen receptor alpha (ERα) protein. This action effectively disrupts the ER signaling pathway, thereby inhibiting the proliferation of ER-positive breast cancer cells and addressing the challenges posed by resistance to conventional endocrine therapies. This mechanism addresses the challenges associated with resistance to conventional endocrine therapies, and SERDs are currently recommended for patients exhibiting disease progression following first-line endocrine treatment3,4. Fulvestrant, the first FDA-approved SERD, introduced in 2002, has demonstrated substantial efficacy; however, its clinical application is limited by its intramuscular administration route and the occurrence of injection site reactions in some patients5. Recently, the approval of oral SERDs, such as elacestrant in January 2023, represents a significant shift in treatment strategies. Data from the Phase III EMERALD study indicate that elacestrant achieved a median progression-free survival (PFS) of 3.8 months in the ESR1-mutant subgroup, compared to 1.9 months with standard therapy, with additional benefits observed when combined with CDK4/6 inhibitors6. Although the efficacy of SERDs has been established through clinical trials, their safety profiles in real-world settings and long-term safety risks are not yet fully understood. The existing evidence is limited by the small sample sizes of randomized controlled trials (RCTs), which hinders a thorough assessment of risk profile heterogeneity across various demographic subgroups, the detection of rare but clinically significant adverse events, and the ability to conduct comprehensive inter-drug safety comparisons among different generations of SERDs (such as oral versus injectable formulations). The FDA Adverse Event Reporting System (FAERS), recognized as the world’s largest spontaneous pharmacovigilance database, is instrumental in capturing rare or delayed adverse drug reactions that occur post-marketing, thereby offering a valuable perspective for assessing the safety of new therapies. This study seeks to analyze adverse event signals related to fulvestrant and elacestrant within the FAERS database. It aims to systematically compare the safety profiles of these two SERDs, identify their common risks, and ultimately enhance clinical decision-making regarding medication use, while providing preliminary evidence that may guide future risk prevention and management strategies. Materials and methods Data extraction and processing Data spanning from the first quarter of 2004 to the fourth quarter of 2024 were extracted from the FAERS database. The search employed the generic names “elacestrant” and “fulvestrant,” in addition to the trade names “Orserdu” and “Faslodex.” The analysis period commenced with the introduction of elacestrant in 2022 and fulvestrant in 2004, concluding in the fourth quarter of 2024. For each case number, only data corresponding to the most recent report date were retained. Entries lacking information for the three core variables—primary ID, drug name, and preferred term (PT)—were excluded to ensure that AE reports identified the target drug as the primary suspected drug. Adverse events were standardized using the PT and system organ class (SOC) from the Medical Dictionary for Regulatory Activities (MedDRA) version 27.07. PT associated with product issues, social context, medication errors, and SERDs indications were excluded. Signal detection methods This study utilized multiple detection methods to identify AE signals, including the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS). The criteria for signal determination were established as follows: six indicators must be concurrently satisfied: (1) the number of adverse event (AE) reports must be at least 3; (2) the lower bound of the 95% confidence interval (CI) for ROR must exceed 1; (3) the PRR value must be no less than 2; (4) the chi-square (χ²) statistic must be greater than 4;(5) the information component (IC025) exceeds 0;(6) the Empirical Bayes Geometric Mean at the 0.5 quantile (EBGM0.5) is greater than 28. Result Basic information of adverse event (AE) reports A total of 15,756 reports were associated with two types of SERDs, specifically 6,636 adverse event reports for elacestrant and 9,120 adverse event reports for fulvestrant. Female patients constituted over 99% of the adverse event reports in both groups. Among reports identifying elacestrant as the primary suspected drug, the highest proportion of patients were those over 65 years of age, consumer-initiated submissions accounted for 86.03%, while healthcare professional-submitted reports constituted 13.09%, respectively. Conversely, in reports where fulvestrant was the primary suspected drug, a larger proportion of patients were aged 18–65 years, consumer-initiated submissions accounted for 25.33%, while healthcare professional-submitted reports constituted 62.79%. Furthermore, the proportion of serious adverse events among reports was higher for fulvestrant (88.21%) compared to elacestrant (35.34%) (Table 1). Table 1Basic characteristics of adverse event reports.CharacteristicsElacestrant-induced adverse event reports (N = 6636)Fulvestrant-induced adverse event reports (N = 9120)Available numberReports numberReports proportion,%Available numberReports numberReports proportion,%Gender6349-95.688193-89.84Female-629199.09-811499.04Male-580.91-790.096Age6178-93.104310-47.26< 18-10.02-30.0718–65-302348.93-247757.47> 65-315451.05-183042.46Mean (SD)Adverse event outcome6636-1009120-100Nonserious-429164.66-107511.79Serious-234535.34-804588.21Reporter type6578-99.128037-88.12CN-570986.03-231125.33HP-67110.11-147216.14MD-1602.41-375041.12PH-380.57-5045.53Country6578-99.129118-99.98US-652694.88-223324.49FR-180.274244.65DE-100.15127213.95CA---106211.65JP---4374.79 Table 1Basic characteristics of adverse event reports.CharacteristicsElacestrant-induced adverse event reports (N = 6636)Fulvestrant-induced adverse event reports (N = 9120)Available numberReports numberReports proportion,%Available numberReports numberReports proportion,%Gender6349-95.688193-89.84Female-629199.09-811499.04Male-580.91-790.096Age6178-93.104310-47.26< 18-10.02-30.0718–65-302348.93-247757.47> 65-315451.05-183042.46Mean (SD)Adverse event outcome6636-1009120-100Nonserious-429164.66-107511.79Serious-234535.34-804588.21Reporter type6578-99.128037-88.12CN-570986.03-231125.33HP-67110.11-147216.14MD-1602.41-375041.12PH-380.57-5045.53Country6578-99.129118-99.98US-652694.88-223324.49FR-180.274244.65DE-100.15127213.95CA---106211.65JP---4374.79 Basic characteristics of adverse event reports. Signal detection results In the analysis of signal detection, fulvestrant was associated with a total of 22 System Organ Classes (SOCs), encompassing 273 valid signals. Conversely, elacestrant was linked to 14 SOCs, with 85 valid signals identified. For elacestrant, the three most frequently reported SOCs were gastrointestinal disorders (n = 3,730; 44.15%), general disorders and administration site conditions (n = 2,100; 24.86%), and musculoskeletal and connective tissue disorders (n = 739; 8.75%). In contrast, the predominant SOCs for fulvestrant included neoplasms benign, malignant, and unspecified (n = 4,965; 37.77%), general disorders and administration site conditions (n = 2,385; 18.14%), and blood and lymphatic system disorders (n = 1,753; 13.33%). Both drugs commonly reported adverse events such as bone pain, disease progression, nausea, and hot flashes (Figs. 1 and 2). Fig. 1System organ class (SOC) classification of adverse events associated with elacestrant. System organ class (SOC) classification of adverse events associated with elacestrant. Fig. 2System organ class (SOC) classification of adverse events associated with fulvestrant. System organ class (SOC) classification of adverse events associated with fulvestrant. Preferred term (PT) analysis in the top 20 reported adverse events Among the top 20 most frequently reported Preferred Terms (PTs), adverse events associated with elacestrant predominantly involved gastrointestinal reactions, specifically nausea, vomiting, and diarrhea. Additionally, adverse events necessitating close monitoring included elevated tumor marker levels, hypercholesterolemia, dehydration, and dysphagia. In contrast, adverse event reports related to fulvestrant have documented an increased incidence of tumor metastasis-related events, indicating a potential risk for disease progression, furthermore, several unexpected adverse reactions not listed in the product labeling have been observed, including neutropenia, leukopenia, hyperglycemia, and interstitial lung disease (Table 2). Table 2Top 20 PTs with highest adverse event report counts.ElacestrantFulvestrantPTAdverse event reports numberROR (95%CI)PRR (χ²)EBGM (EBGM05)BCPNN (IC025)PTAdverse event reports numberROR (95%CI)PRR (χ²)EBGM (EBGM05)BCPNN (IC025)Nausea13727.59 (7.18 ~ 8.02)7.08 (7190.82)7.04(6.66)2.81 (2.72)Malignant neoplasm progression162330.35 (28.86 ~ 31.91)29.02 (43177.66)28.51 (27.11)4.83 (4.73)Fatigue10184.68 (4.40 ~ 4.99)4.47 (2767.51)4.46(4.18)2.16 (2.06)Death12842.66 (2.51 ~ 2.81)2.60 (1276.24)2.59 (2.45)1.38 (1.29)Disease progression77720.72 (19.27 ~ 22.28)19.86 (13680.06)19.5 (18.13)4.29 (4.14)Neutropenia6949.16 (8.49 ~ 9.88)9.00 (4918.39)8.96 (8.31)3.1 (3.03)Vomiting6185.64 (5.20 ~ 6.11)5.47 (2261.92)5.45 (5.03)2.45 (2.32)Metastases to bone63073.64 (67.94 ~ 79.82)72.36 (42374.54)69.19 (63.83)6.11 (5.85)Diarrhoea5012.80 (2.56 ~ 3.06)2.74 (559.99)2.74(2.51)1.45 (1.32)Metastases to liver49551.87 (47.40 ~ 56.77)51.17 (23580.02)49.57 (45.30)5.63 (5.37)Constipation3696.17 (5.57 ~ 6.84)6.06 (1556.51)6.03(5.44)2.59 (2.42)Breast cancer metastatic47080.53 (73.35 ~ 88.40)79.48 (34656.52)75.66 (68.93)6.24 (5.89)Decreased appetite3415.27 (4.73 ~ 5.87)5.19 (1150.52)5.16 (4.64)2.37 (2.19)Anaemia3122.79 (2.50 ~ 3.12)2.78 (355.47)2.77 (2.48)1.47(1.30)Arthralgia3092.42 (2.16 ~ 2.71)2.39 (251.95)2.39 (2.13)1.26 (1.08)Leukopenia2398.37 (7.36 ~ 9.50)8.32 (1531.46)8.28 (7.29)3.05(2.82)Asthenia2242.36 (2.07 ~ 2.69)2.34 (172.39)2.34 (2.05)1.22 (1.02)Thrombocytopenia2373.71 (3.26 ~ 4.21)3.69 (464.70)3.68 (3.24)1.88(1.68)Dyspepsia2189.25 (8.09 ~ 10.58)9.15 (1570.69)9.08 (7.94)3.18 (2.93)White blood cell count decreased2253.57 (3.13 ~ 4.07)3.55 (412.72)3.55 (3.11)1.83 (1.62)Abdominal discomfort2154.26 (3.73 ~ 4.88)4.22 (528.22)4.21 (3.68)2.07 (1.85)Metastases to lung21734.22 (29.91 ~ 39.17)34.02 (6807.63)33.32 (29.11)5.06 (4.66)Tumour marker increased206119.00 (102.95 ~ 137.56)117.63 (21372.24)105.63 (91.38)6.72 (5.93)Pleural effusion1865.19 (4.50 ~ 6.00)5.17 (624.51)5.16 (4.46)2.37 (2.12)Myalgia1965.19 (4.50 ~ 5.97)5.14 (651.67)5.12 (4.45)2.36 (2.12)Tumour marker increased17163.23 (54.25 ~ 73.70)62.94 (10017.73)60.52 (51.93)5.92 (5.27)Hot flush1838.80 (7.60 ~ 10.19)8.72 (1241.61)8.65 (7.48)3.11 (2.84)Neutrophil count decreased1486.51 (5.54 ~ 7.65)6.48 (684.16)6.46 (5.50)2.69 (2.40)Abdominal pain upper1583.05 (2.60 ~ 3.56)3.03 (214.52)3.02 (2.58)1.60 (1.35)Hyperglycaemia1456.85 (5.82 ~ 8.07)6.83 (718.37)6.80 (5.78)2.77 (2.47)Bone pain15111.06 (9.41 ~ 12.99)10.97 (1354.96)10.87 (9.25)3.44 (3.11)Hot flush1303.12 (2.63 ~ 3.71)3.12 (186.73)3.11 (2.62)1.64 (1.36)Blood cholesterol increased12410.74 (9.00 ~ 12.83)10.67 (1076.77)10.57 (8.85)3.40 (3.04)Bone pain1263.70 (3.10 ~ 4.40)3.69 (246.28)3.68 (3.09)1.88 (1.59)Gastroesophageal reflux disease954.85 (3.96 ~ 5.94)4.83 (287.53)4.81 (3.93)2.27 (1.91)Metastases to lymph nodes11431.24 (25.94 ~ 37.61)31.14 (3260.58)30.55 (25.37)4.93 (4.33)Dehydration873.01 (2.44 ~ 3.72)3.00 (115.96)3.00 (2.43)1.58 (1.24)Osteonecrosis of jaw1006.67 (5.48 ~ 8.12)6.65 (478.27)6.63 (5.44)2.73 (2.36)Malignant neoplasm progression692.96 (2.34 ~ 3.75)2.95 (89.03)2.95 (2.33)1.56 (1.17)Interstitial lung disease993.61 (2.96 ~ 4.40)3.60 (185.71)3.60 (2.95)1.85 (1.52) Table 2Top 20 PTs with highest adverse event report counts.ElacestrantFulvestrantPTAdverse event reports numberROR (95%CI)PRR (χ²)EBGM (EBGM05)BCPNN (IC025)PTAdverse event reports numberROR (95%CI)PRR (χ²)EBGM (EBGM05)BCPNN (IC025)Nausea13727.59 (7.18 ~ 8.02)7.08 (7190.82)7.04(6.66)2.81 (2.72)Malignant neoplasm progression162330.35 (28.86 ~ 31.91)29.02 (43177.66)28.51 (27.11)4.83 (4.73)Fatigue10184.68 (4.40 ~ 4.99)4.47 (2767.51)4.46(4.18)2.16 (2.06)Death12842.66 (2.51 ~ 2.81)2.60 (1276.24)2.59 (2.45)1.38 (1.29)Disease progression77720.72 (19.27 ~ 22.28)19.86 (13680.06)19.5 (18.13)4.29 (4.14)Neutropenia6949.16 (8.49 ~ 9.88)9.00 (4918.39)8.96 (8.31)3.1 (3.03)Vomiting6185.64 (5.20 ~ 6.11)5.47 (2261.92)5.45 (5.03)2.45 (2.32)Metastases to bone63073.64 (67.94 ~ 79.82)72.36 (42374.54)69.19 (63.83)6.11 (5.85)Diarrhoea5012.80 (2.56 ~ 3.06)2.74 (559.99)2.74(2.51)1.45 (1.32)Metastases to liver49551.87 (47.40 ~ 56.77)51.17 (23580.02)49.57 (45.30)5.63 (5.37)Constipation3696.17 (5.57 ~ 6.84)6.06 (1556.51)6.03(5.44)2.59 (2.42)Breast cancer metastatic47080.53 (73.35 ~ 88.40)79.48 (34656.52)75.66 (68.93)6.24 (5.89)Decreased appetite3415.27 (4.73 ~ 5.87)5.19 (1150.52)5.16 (4.64)2.37 (2.19)Anaemia3122.79 (2.50 ~ 3.12)2.78 (355.47)2.77 (2.48)1.47(1.30)Arthralgia3092.42 (2.16 ~ 2.71)2.39 (251.95)2.39 (2.13)1.26 (1.08)Leukopenia2398.37 (7.36 ~ 9.50)8.32 (1531.46)8.28 (7.29)3.05(2.82)Asthenia2242.36 (2.07 ~ 2.69)2.34 (172.39)2.34 (2.05)1.22 (1.02)Thrombocytopenia2373.71 (3.26 ~ 4.21)3.69 (464.70)3.68 (3.24)1.88(1.68)Dyspepsia2189.25 (8.09 ~ 10.58)9.15 (1570.69)9.08 (7.94)3.18 (2.93)White blood cell count decreased2253.57 (3.13 ~ 4.07)3.55 (412.72)3.55 (3.11)1.83 (1.62)Abdominal discomfort2154.26 (3.73 ~ 4.88)4.22 (528.22)4.21 (3.68)2.07 (1.85)Metastases to lung21734.22 (29.91 ~ 39.17)34.02 (6807.63)33.32 (29.11)5.06 (4.66)Tumour marker increased206119.00 (102.95 ~ 137.56)117.63 (21372.24)105.63 (91.38)6.72 (5.93)Pleural effusion1865.19 (4.50 ~ 6.00)5.17 (624.51)5.16 (4.46)2.37 (2.12)Myalgia1965.19 (4.50 ~ 5.97)5.14 (651.67)5.12 (4.45)2.36 (2.12)Tumour marker increased17163.23 (54.25 ~ 73.70)62.94 (10017.73)60.52 (51.93)5.92 (5.27)Hot flush1838.80 (7.60 ~ 10.19)8.72 (1241.61)8.65 (7.48)3.11 (2.84)Neutrophil count decreased1486.51 (5.54 ~ 7.65)6.48 (684.16)6.46 (5.50)2.69 (2.40)Abdominal pain upper1583.05 (2.60 ~ 3.56)3.03 (214.52)3.02 (2.58)1.60 (1.35)Hyperglycaemia1456.85 (5.82 ~ 8.07)6.83 (718.37)6.80 (5.78)2.77 (2.47)Bone pain15111.06 (9.41 ~ 12.99)10.97 (1354.96)10.87 (9.25)3.44 (3.11)Hot flush1303.12 (2.63 ~ 3.71)3.12 (186.73)3.11 (2.62)1.64 (1.36)Blood cholesterol increased12410.74 (9.00 ~ 12.83)10.67 (1076.77)10.57 (8.85)3.40 (3.04)Bone pain1263.70 (3.10 ~ 4.40)3.69 (246.28)3.68 (3.09)1.88 (1.59)Gastroesophageal reflux disease954.85 (3.96 ~ 5.94)4.83 (287.53)4.81 (3.93)2.27 (1.91)Metastases to lymph nodes11431.24 (25.94 ~ 37.61)31.14 (3260.58)30.55 (25.37)4.93 (4.33)Dehydration873.01 (2.44 ~ 3.72)3.00 (115.96)3.00 (2.43)1.58 (1.24)Osteonecrosis of jaw1006.67 (5.48 ~ 8.12)6.65 (478.27)6.63 (5.44)2.73 (2.36)Malignant neoplasm progression692.96 (2.34 ~ 3.75)2.95 (89.03)2.95 (2.33)1.56 (1.17)Interstitial lung disease993.61 (2.96 ~ 4.40)3.60 (185.71)3.60 (2.95)1.85 (1.52) Top 20 PTs with highest adverse event report counts. 7.04 (6.66) 4.46 (4.18) 5.45 (5.03) 2.74 (2.51) 6.03 (5.44) 2.77 (2.48) 1.47 (1.30) 2.39 (2.13) 1.26 (1.08) 8.28 (7.29) 3.05 (2.82) 2.34 (2.05) 3.68 (3.24) 1.88 (1.68) Among the top 20 PTs ranked by signal intensity, those associated with elacestrant, including abnormal tumor markers, abnormal scans, esophageal burns, esophageal irritation, and foreign body sensation in the throat, demonstrated heightened signal intensity. Notably, these reactions were not described in the drug’s current labeling and may warrant further investigation. In contrast, for fulvestrant, adverse events such as renal impairment (isosthenuria), metastases to the chest wall/thoracic cavity/pleura, mediastinal fibrosis, thyroid calcification, red blood cell fragment syndrome, pulmonary septal thickening, and pre-hypertension exhibited a stronger association with drug use, indicating potential underlying causal relationships (Table 3). Table 3Top 20 PTs with highest adverse event signal counts.ElacestrantFulvestrantPTAdverse event reports numberROR (95%CI)PRR (χ²))EBGM (EBGM05)BCPNN (IC025)PTAdverse event reports numberROR (95%CI)PRR (χ²)EBGM (EBGM05)BCPNN (IC025)Carbohydrate antigen 27.29 increased15384.90 (212.59 ~ 696.86)384.57 (4173.57)279.96 (154.63)8.13 (3.20)Isosthenuria5456.88 (168.55 ~ 1238.45)456.81 (1757.25)353.22 (130.31)8.46 (1.38)Tumour marker increased206119.00 (102.94 ~ 137.56)117.63 (21372.24)105.63 (91.38)6.72 (5.93)pik3ca-activated mutation55368.77 (274.80 ~ 494.88)368.21 (16281.78)297.84 (221.94)8.22 (5.18)Scan abnormal1291.22 (50.54 ~ 164.66)91.16 (982.69)83.80 (46.42)6.39 (2.70)Carbohydrate antigen 15 − 3 increased88227.60 (181.93 ~ 284.72)227.04 (17278.49)198.21 (158.45)7.63 (5.64)Positron emission tomography abnormal1973.06 (45.86 ~ 116.38)72.98 (1259.25)68.20 (42.81)6.09 (3.32)Mediastinal fibrosis5209.92 (82.50 ~ 534.14)209.89 (915.72)185.02 (72.71)7.53 (1.37)Tumour marker abnormal1060.01 (31.71 ~ 113.55)59.97 (547.86)56.71 (29.97)5.82 (2.35)Thyroid calcification5165.25 (65.72 ~ 415.52)165.23 (737.70)149.44 (59.43)7.22 (1.36)Burn oesophageal547.06 (19.20 ~ 115.34)47.04 (215.44)45.02 (18.37)5.49 (1.25)Red cell fragmentation syndrome4147.94 (53.04 ~ 412.59)147.92 (532.95)135.14 (48.46)7.08 (0.99)Oesophageal irritation539.45 (16.15 ~ 96.40)39.44 (180.41)38.02(15.56)5.25 (1.22)Pulmonary septal thickening5131.64 (52.83 ~ 328.02)131.62 (597.52)121.42 (48.73)6.92 (1.35)Foreign body in gastrointestinal tract431.32 (11.58 ~ 84.71)31.31 (113.91)30.42(11.24)4.93 (0.85)Prehypertension5129.45 (51.98 ~ 322.36)129.43 (588.18)119.55 (48.01)6.90 (1.34)Bone neoplasm829.31 (14.51 ~ 59.20)29.30 (212.61)28.51(14.12)4.83 (1.85)Metastases to spinal cord11122.07 (66.07 ~ 225.53)122.03 (1224.28)113.22 (61.28)6.82 (2.62)Foreign body in throat4725.43 (19.03 ~ 33.98)25.37 (1073.72)24.78(18.54)4.63 (3.63)Spinal cord haematoma1199.94 (54.32 ~ 183.89)99.91 (1012.04)93.93 (51.05)6.55 (2.59)Carbohydrate antigen 15 − 3 increased924.62 (12.71 ~ 47.71)24.61 (199.11)24.06 (12.42)4.59 (1.95)Malignant neoplasm oligoprogression495.59 (34.82 ~ 262.39)95.58 (352.66)90.10 (32.82)6.49 (0.97)Disease progression77720.72 (19.27 ~ 22.28)19.86 (13680.06)19.5 (18.13)4.29 (4.14)Metastases to chest wall1792.04 (56.42 ~ 150.15)92.00 (1444.61)86.91 (53.28)6.44 (3.23)Hepatic neoplasm1216.31 (9.22 ~ 28.85)16.30 (169.64)16.06 (9.08)4.01 (2.09)Metastases to thorax1285.13 (47.61 ~ 152.23)85.11 (945.59)80.74 (45.15)6.34 (2.70)Cancer pain1415.63 (9.22 ~ 26.51)15.62 (188.75)15.40 (9.08)3.95 (2.23)Metastases to nervous system781.15 (37.95 ~ 173.52)81.14 (526.53)77.16 (36.08)6.27 (1.85)Spinal cord neoplasm412.47 (4.65 ~ 33.43)12.47 (41.69)12.33 (4.60)3.62 (0.62)Breast cancer metastatic47080.53 (73.35 ~ 88.40)79.48 (34656.52)75.66 (68.93)6.24 (5.89)Lipids increased611.66 (5.21 ~ 26.07)11.65 (57.78)11.53 (5.16)3.53 (1.11)Metastases to pleura4177.37 (56.53 ~ 105.89)77.28 (2940.79)73.67 (53.83)6.20 (4.31)Bone pain15111.06 (9.41 ~ 12.99)10.97 (1354.96)10.87 (9.25)3.44 (3.11)Bone sequestrum675.78 (33.39 ~ 171.97)75.76 (422.08)72.29 (31.85)6.18 (1.06)Carcinoembryonic antigen increased710.93 (5.19 ~ 23.02)10.93 (62.46)10.82 (5.14)3.44 (1.26)Intestinal metastasis1374.26 (42.56 ~ 129.55)74.23 (896.36)70.89 (40.63)6.15 (2.79)Blood cholesterol increased12410.74 (9.00 ~ 12.83)10.67 (1076.77)10.57 (8.85)3.40 (3.04)Metastases to bone63073.64 (67.94 ~ 79.82)72.36 (42374.54)69.19 (63.83)6.11 (5.85)Blood electrolytes decreased49.56 (3.57 ~ 25.60)9.56 (30.38)9.48 (3.54)3.25 (0.52)Metastases to ovary1270.36 (39.45 ~ 125.48)70.33 (784.63)67.33 (37.75)6.07 (2.66) Table 3Top 20 PTs with highest adverse event signal counts.ElacestrantFulvestrantPTAdverse event reports numberROR (95%CI)PRR (χ²))EBGM (EBGM05)BCPNN (IC025)PTAdverse event reports numberROR (95%CI)PRR (χ²)EBGM (EBGM05)BCPNN (IC025)Carbohydrate antigen 27.29 increased15384.90 (212.59 ~ 696.86)384.57 (4173.57)279.96 (154.63)8.13 (3.20)Isosthenuria5456.88 (168.55 ~ 1238.45)456.81 (1757.25)353.22 (130.31)8.46 (1.38)Tumour marker increased206119.00 (102.94 ~ 137.56)117.63 (21372.24)105.63 (91.38)6.72 (5.93)pik3ca-activated mutation55368.77 (274.80 ~ 494.88)368.21 (16281.78)297.84 (221.94)8.22 (5.18)Scan abnormal1291.22 (50.54 ~ 164.66)91.16 (982.69)83.80 (46.42)6.39 (2.70)Carbohydrate antigen 15 − 3 increased88227.60 (181.93 ~ 284.72)227.04 (17278.49)198.21 (158.45)7.63 (5.64)Positron emission tomography abnormal1973.06 (45.86 ~ 116.38)72.98 (1259.25)68.20 (42.81)6.09 (3.32)Mediastinal fibrosis5209.92 (82.50 ~ 534.14)209.89 (915.72)185.02 (72.71)7.53 (1.37)Tumour marker abnormal1060.01 (31.71 ~ 113.55)59.97 (547.86)56.71 (29.97)5.82 (2.35)Thyroid calcification5165.25 (65.72 ~ 415.52)165.23 (737.70)149.44 (59.43)7.22 (1.36)Burn oesophageal547.06 (19.20 ~ 115.34)47.04 (215.44)45.02 (18.37)5.49 (1.25)Red cell fragmentation syndrome4147.94 (53.04 ~ 412.59)147.92 (532.95)135.14 (48.46)7.08 (0.99)Oesophageal irritation539.45 (16.15 ~ 96.40)39.44 (180.41)38.02(15.56)5.25 (1.22)Pulmonary septal thickening5131.64 (52.83 ~ 328.02)131.62 (597.52)121.42 (48.73)6.92 (1.35)Foreign body in gastrointestinal tract431.32 (11.58 ~ 84.71)31.31 (113.91)30.42(11.24)4.93 (0.85)Prehypertension5129.45 (51.98 ~ 322.36)129.43 (588.18)119.55 (48.01)6.90 (1.34)Bone neoplasm829.31 (14.51 ~ 59.20)29.30 (212.61)28.51(14.12)4.83 (1.85)Metastases to spinal cord11122.07 (66.07 ~ 225.53)122.03 (1224.28)113.22 (61.28)6.82 (2.62)Foreign body in throat4725.43 (19.03 ~ 33.98)25.37 (1073.72)24.78(18.54)4.63 (3.63)Spinal cord haematoma1199.94 (54.32 ~ 183.89)99.91 (1012.04)93.93 (51.05)6.55 (2.59)Carbohydrate antigen 15 − 3 increased924.62 (12.71 ~ 47.71)24.61 (199.11)24.06 (12.42)4.59 (1.95)Malignant neoplasm oligoprogression495.59 (34.82 ~ 262.39)95.58 (352.66)90.10 (32.82)6.49 (0.97)Disease progression77720.72 (19.27 ~ 22.28)19.86 (13680.06)19.5 (18.13)4.29 (4.14)Metastases to chest wall1792.04 (56.42 ~ 150.15)92.00 (1444.61)86.91 (53.28)6.44 (3.23)Hepatic neoplasm1216.31 (9.22 ~ 28.85)16.30 (169.64)16.06 (9.08)4.01 (2.09)Metastases to thorax1285.13 (47.61 ~ 152.23)85.11 (945.59)80.74 (45.15)6.34 (2.70)Cancer pain1415.63 (9.22 ~ 26.51)15.62 (188.75)15.40 (9.08)3.95 (2.23)Metastases to nervous system781.15 (37.95 ~ 173.52)81.14 (526.53)77.16 (36.08)6.27 (1.85)Spinal cord neoplasm412.47 (4.65 ~ 33.43)12.47 (41.69)12.33 (4.60)3.62 (0.62)Breast cancer metastatic47080.53 (73.35 ~ 88.40)79.48 (34656.52)75.66 (68.93)6.24 (5.89)Lipids increased611.66 (5.21 ~ 26.07)11.65 (57.78)11.53 (5.16)3.53 (1.11)Metastases to pleura4177.37 (56.53 ~ 105.89)77.28 (2940.79)73.67 (53.83)6.20 (4.31)Bone pain15111.06 (9.41 ~ 12.99)10.97 (1354.96)10.87 (9.25)3.44 (3.11)Bone sequestrum675.78 (33.39 ~ 171.97)75.76 (422.08)72.29 (31.85)6.18 (1.06)Carcinoembryonic antigen increased710.93 (5.19 ~ 23.02)10.93 (62.46)10.82 (5.14)3.44 (1.26)Intestinal metastasis1374.26 (42.56 ~ 129.55)74.23 (896.36)70.89 (40.63)6.15 (2.79)Blood cholesterol increased12410.74 (9.00 ~ 12.83)10.67 (1076.77)10.57 (8.85)3.40 (3.04)Metastases to bone63073.64 (67.94 ~ 79.82)72.36 (42374.54)69.19 (63.83)6.11 (5.85)Blood electrolytes decreased49.56 (3.57 ~ 25.60)9.56 (30.38)9.48 (3.54)3.25 (0.52)Metastases to ovary1270.36 (39.45 ~ 125.48)70.33 (784.63)67.33 (37.75)6.07 (2.66) Top 20 PTs with highest adverse event signal counts. 38.02 (15.56) 30.42 (11.24) 28.51 (14.12) 24.78 (18.54) Discussion Selective estrogen receptor degraders (SERDs) represent an innovative class of therapeutic agents that offer notable advantages in overcoming resistance to endocrine therapy, particularly resistance mediated by mutations in the ESR1 gene, thereby providing new treatment options for patients who have not responded to conventional endocrine therapies. Among these agents, elacestrant emerges as a promising candidate for first-line monotherapy. It is orally bioavailable and minimally impacted by first-pass metabolism, allowing for effective systemic circulation via gastrointestinal absorption. Elacestrant maintains strong degradation activity against key resistance mutations such as Y537S and D538G, which constitute approximately 40% of clinically prevalent ESR1 alterations9. When used in combination with PI3K inhibitors or mTOR inhibitors, elacestrant demonstrates synergistic effects that enhance its efficacy against resistant pathways10. Additionally, oral SERDs have the capacity to penetrate the blood-brain barrier, thereby conferring therapeutic benefits to breast cancer patients with brain metastases11. In contrast, fulvestrant demonstrates limited efficacy as a monotherapy in patients with ESR1 mutations, characterized by broad tissue distribution and reduced specificity for target tissues, and does not provide additional clinical benefits for patients who have previously received fulvestrant treatment. Nonetheless, a subgroup analysis from the SOFEA trial revealed that the combination of fulvestrant and exemestane resulted in a median PFS of 5.7 months in patients with ESR1 mutations who had experienced failure with aromatase inhibitor (AI) therapy. This outcome was significantly superior to that of exemestane monotherapy, which achieved a PFS of 2.9 months (HR = 0.52), indicating residual therapeutic efficacy in this specific cohort12. Currently, the combination of fulvestrant with CDK4/6 inhibitors remains a standard treatment option; however, its status as a first-line therapy has gradually been overtaken by oral SERDs. In terms of safety profiles, fulvestrant is frequently linked to injection site reactions, fatigue, nausea, and elevated hepatic enzyme levels13,14. Conversely, elacestrant is primarily associated with adverse effects such as musculoskeletal pain, hepatic dysfunction, gastrointestinal disturbances, hyponatremia, and headache15,16. Importantly, these reactions are generally mild to moderate in severity and can be effectively managed through therapeutic interventions, such as dose optimization or symptomatic supportive care17. Through an analysis of the FAERS database, this study identified that common adverse events associated with the sSERDs elacestrant and fulvestrant include bone pain, disease progression, gastrointestinal reactions, and hot flashes. Notably, elacestrant was associated with a lower incidence of severe adverse events, with gastrointestinal reactions, abnormal tumor marker levels, and esophageal-related reactions being the most prevalent. In contrast, fulvestrant was linked to a higher incidence of tumor metastasis and potential involvement of the hematologic/lymphatic, cardiovascular, and respiratory systems. Elacestrant Cancer Antigen (CA) 27.29 is a monoclonal antibody that targets the glycoprotein MUC1, which is expressed on the apical surface of normal epithelial cells. CA 27.29 is significantly associated with breast cancer, with elevated levels observed in approximately one-third of women with early-stage breast cancer (stage I or II) and two-thirds of those with advanced breast cancer (stage III or IV)18. The mechanism underlying the elacestrant-induced elevation of tumor markers may be attributed to its rapid induction of tumor cell death, whereby the release of specific markers from deceased tumor cells into the bloodstream results in a transient increase in serum biomarkers. This phenomenon has also been reported in the context of certain chemotherapeutic and targeted therapies19. When patients are administered concurrent chemotherapy, immunotherapy, or other targeted agents, the potential additive effects on tumor marker levels should be taken into consideration. Additionally, elacestrant may lead to elevated AST/ALT levels, indicating potential hepatocyte impairment. Given that the liver is a central organ in lipid metabolism, its dysfunction can directly disrupt lipid homeostasis. Furthermore, hyperlipidemia may exacerbate hepatic injury, thereby creating a self-perpetuating cycle of damage20,21. The most prevalent adverse reactions associated with elacestrant are nausea, vomiting, diarrhea, and similar symptoms, which tend to be more pronounced during the initial phase of treatment. Frequent vomiting can result in a significant loss of gastric fluids and oral secretions, potentially leading to isotonic or hypotonic dehydration. Diarrhea, resulting from increased intestinal secretion and decreased absorption, may cause substantial fluid and electrolyte losses (e.g., sodium, potassium), further predisposing patients to hypotonic dehydration. Moreover, reduced fluid intake due to drug-induced gastrointestinal discomfort or decreased appetite may exacerbate the risk of dehydration22. Although there is no direct evidence linking elacestrant to dysphagia or esophageal irritation, its gastrointestinal side effects may indirectly contribute to these symptoms. Persistent gastrointestinal reactions could lead to pharyngeal muscle fatigue or increased sensitivity, resulting in transient dysphagia, gastroesophageal reflux, and esophageal irritation, which may ultimately cause pharyngeal mucosal inflammation23. Clinically, the presence of dysphagia should prompt a thorough evaluation of alternative etiologies and adherence to individualized management strategies. Fulvestrant​ This study, utilizing real-world evidence, identified that fulvestrant is associated with an increased incidence of severe adverse events and a heightened risk of cancer metastasis in clinical practice. In comparison to anastrozole, fulvestrant significantly extended PFS in patients with advanced breast cancer. However, a subset of patients still experienced disease progression during treatment, suggesting that drug resistance may be a primary factor driving this progression24. Emerging mechanistic studies indicate that the coexistence of ESR1 F404L and activating mutations, such as E380Q, disrupts fulvestrant’s π-stacking interactions with ER, thereby substantially diminishing drug sensitivity. Notably, these mutations were observed exclusively under fulvestrant exposure, suggesting their potential role as specific resistance mechanisms25. The hematolymphatic toxicity observed with fulvestrant administration may be linked to the myelosuppressive properties of antineoplastic agents, which include the inhibition of hematopoietic stem cell proliferation, disruption of platelet and erythrocyte production, and modification of the hematopoietic microenvironment26. Importantly, the combination of fulvestrant with CDK4/6 inhibitors, such as dalpiciclib, has been shown to further significantly decrease hemoglobin levels and leukocyte counts in patients. Moreover, neutropenia—a key toxicity associated with CDK4/6 inhibitors due to cell cycle arrest—may be exacerbated in this combination therapy27. These observations indicate that the concurrent administration of fulvestrant and CDK4/6 inhibitors may synergistically intensify bone marrow suppression, thereby exerting more pronounced effects on hematopoietic function28. The mechanism underlying fulvestrant-associated hyperglycemia may be attributed to hepatic dysfunction, wherein hepatic impairment can result in increased lipolysis, elevated levels of free fatty acids (FFA), diminished hepatic insulin sensitivity, and subsequent induction of insulin resistance, ultimately leading to elevated blood glucose levels29. In the SOLAR-1 trial, the incidence rate of hyperglycemia of all grades among patients with HR+/HER2 − advanced breast cancer receiving alpelisib in combination with fulvestrant was 65.8%, with grade 3/4 hyperglycemia accounting for 38%30. This suggests that for patients concurrently receiving PI3Kα inhibitors (e.g., alpelisib), early identification and intervention of hyperglycemia risk are essential to improve patient outcomes. Interstitial lung disease (ILD) is a common pulmonary adverse event associated with the clinical application of antineoplastic drugs, and its pathogenesis may involve direct cytotoxic damage to lung tissue or immune-mediated injury31,32. ILD lacks specific clinical manifestations, and some patients may present with systemic symptoms such as dry cough, fatigue, fever, and rash33. Our findings indicate that in patients with pre-existing pulmonary comorbidities, an exacerbation of existing respiratory symptoms and/or signs during fulvestrant therapy necessitates increased vigilance for the risk of ILD, especially in the context of combination regimens. Moreover, there is insufficient evidence to establish a causal link between fulvestrant and thyroid calcification; thyroid-related adverse events reported may be attributable to underlying thyroid pathology or confounding factors. In terms of renal impairment, kidney injury associated with fulvestrant may result from gastrointestinal side effects such as diarrhea and vomiting, which can lead to dehydration and significant fluid loss. This fluid loss can reduce the effective circulating blood volume and decrease renal arterial perfusion pressure. To maintain fluid homeostasis, the kidneys may constrict efferent glomerular arterioles to decrease filtration, ultimately causing the accumulation of metabolic waste products (e.g., creatinine, blood urea nitrogen)34. Limitation This study is subject to several limitations: First, the analysis does not account for the precise timing of adverse event occurrences, thereby precluding an evaluation of their potential relationships with treatment duration or specific exposure periods. Second, the study does not consider drug combinations or potential drug interactions, which may compromise the accuracy of the results. Third, a substantial proportion of adverse event reports are submitted by consumers, such as patients or family members, potentially introducing information bias and affecting the assessment of event severity and actual occurrence frequency. Lastly, the lack of access to detailed patient baseline information, particularly concerning coexisting comorbidities, hinders the ability to control for the impact of these potential confounding factors on drug-induced adverse events. Conclusion Based on findings from real-world data research, estrogen receptor degraders (ERDs) generally demonstrate manageable safety profiles; however, there are notable variations in the adverse reaction profiles among different drugs. Elacestrant, as an oral formulation, significantly enhances patient adherence to medication compared to traditional injectable formulations and is associated with a lower incidence of severe adverse events. Conversely, while fulvestrant generally maintains a favorable safety profile, it necessitates careful monitoring for the risk of cancer metastatic progression and adverse events affecting the hematologic/lymphatic and respiratory systems. These risks may be further exacerbated when fulvestrant is used in conjunction with targeted therapies such as CDK4/6 inhibitors or PI3Kα inhibitors. In clinical practice, the decision between elacestrant and fulvestrant requires a thorough evaluation of multiple factors, including tumor stage, prior treatment history, concomitant medication regimens, drug availability, and individual patient tolerance. This comprehensive assessment is crucial to balancing treatment safety and efficacy, ultimately achieving the goal of individualized precision therapy. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2